Cargando…

Immunotherapeutic approaches to ovarian cancer treatment

Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for ovarian cancer patients are inadequate. Immunotherapy offers a novel and promising therapeutic strategy for treating ovarian tumors. Following the de...

Descripción completa

Detalles Bibliográficos
Autores principales: Chester, Cariad, Dorigo, Oliver, Berek, Jonathan S, Kohrt, Holbrook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372273/
https://www.ncbi.nlm.nih.gov/pubmed/25806106
http://dx.doi.org/10.1186/s40425-015-0051-7
_version_ 1782363150500233216
author Chester, Cariad
Dorigo, Oliver
Berek, Jonathan S
Kohrt, Holbrook
author_facet Chester, Cariad
Dorigo, Oliver
Berek, Jonathan S
Kohrt, Holbrook
author_sort Chester, Cariad
collection PubMed
description Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for ovarian cancer patients are inadequate. Immunotherapy offers a novel and promising therapeutic strategy for treating ovarian tumors. Following the demonstration of the immunogenicity of ovarian tumors, multiple immunotherapeutic modalities have been developed. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor-modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery.
format Online
Article
Text
id pubmed-4372273
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43722732015-03-25 Immunotherapeutic approaches to ovarian cancer treatment Chester, Cariad Dorigo, Oliver Berek, Jonathan S Kohrt, Holbrook J Immunother Cancer Review Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for ovarian cancer patients are inadequate. Immunotherapy offers a novel and promising therapeutic strategy for treating ovarian tumors. Following the demonstration of the immunogenicity of ovarian tumors, multiple immunotherapeutic modalities have been developed. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor-modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery. BioMed Central 2015-03-24 /pmc/articles/PMC4372273/ /pubmed/25806106 http://dx.doi.org/10.1186/s40425-015-0051-7 Text en © Kohrt et al; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Chester, Cariad
Dorigo, Oliver
Berek, Jonathan S
Kohrt, Holbrook
Immunotherapeutic approaches to ovarian cancer treatment
title Immunotherapeutic approaches to ovarian cancer treatment
title_full Immunotherapeutic approaches to ovarian cancer treatment
title_fullStr Immunotherapeutic approaches to ovarian cancer treatment
title_full_unstemmed Immunotherapeutic approaches to ovarian cancer treatment
title_short Immunotherapeutic approaches to ovarian cancer treatment
title_sort immunotherapeutic approaches to ovarian cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372273/
https://www.ncbi.nlm.nih.gov/pubmed/25806106
http://dx.doi.org/10.1186/s40425-015-0051-7
work_keys_str_mv AT chestercariad immunotherapeuticapproachestoovariancancertreatment
AT dorigooliver immunotherapeuticapproachestoovariancancertreatment
AT berekjonathans immunotherapeuticapproachestoovariancancertreatment
AT kohrtholbrook immunotherapeuticapproachestoovariancancertreatment